Phase 4 N=15 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: 68Ga-DOTATATE Uptake With Cardia Sarcoidosis (CS)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=826 MedStar Diabetes Pathway Chart Reviews
Type2 Diabetes Mellitus
Primary: Percent Change in A1C — -3.06; -1.44 % change — p=<0.001
N/A N=86 Increasing Physical Activity Among Sedentary Older Adults:What, Where, When, and With Whom
Sedentary Lifestyle · Self Efficacy · Control Locus
Primary: Number of Steps Walked — 3910.37; 3477.66; 5744.00; 5279.66 Average Daily Steps — p=< .001
N/A N=13 Desaturation Validation of INVSENSOR00038
Healthy
Primary: Trending Accuracy of INVSENSOR00038 — 2.5 percentage of regional oxygen saturation
N/A N=129 Evaluation of CRB in PROM Patients
Premature Rupture of Fetal Membranes
Primary: Time of Labor — 850.4; 1016.6 Minutes
Phase 2 N=5 Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Lipodystrophy
Primary: Change in Log 10 Fasting Triglycerides. — 0.1; -0.2 log 10 mg/dl
Phase 3 N=172 Study of T-PRED(TM) Compared to Pred Forte(R) II
Cataract
Primary: Means Aqueous Humor Prednisolone Acetate Concentration — 100.02; 131.65 ng/mL
Phase 3 N=140 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 5.2; 1.5; 6.4; 2.2 Points seen — p=<0.0001
Phase 1 N=47 Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.
Enoxaparin Sodium is Administered to Healthy Volunteers
Primary: Cmax (Anti-FXa and Anti-FIIa) — 0.8593; 0.8698; 0.1187; 0.1296 IU/mL
N/A N=30 Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Gastrointestinal Cancer · Nausea Post Chemotherapy
Primary: Percentage of Participants With Control of Vomiting and Rescue Medication Control — 26.9 percentage of participants
N/A N=17 Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias
Atrial Fibrillation · Arrhythmias, Cardiac · Atrial Flutter
Primary: Atrial Fibrillation or Atrial Flutter (AF) of at Least 30 Seconds Duration — 0.11 Proportion of participants
Phase 2 N=21 Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Actinic Keratosis
Primary: Number of Responders — 19 Participants
N/A N=23 Desaturation Validation of INVSENSOR00036
Healthy
Primary: Trending Accuracy of INVSENSOR00036 — 1.8 percentage of regional oxygen saturation
Phase 3 N=855 Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
Overactive Bladder
Primary: The Percentage of Participants Who Did Not Stop Use When They Either Developed a New Symptom Referred to Anywhere in the Labeling or When Their Condition Worsened…
Phase 2 N=34 A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks
Sleep Apnea · Sleep Disordered Breathing
Primary: Change in Apnea Hypopnea Index (AHI) From Baseline — 38.2; 34 apnea / hypopnea events per hour sleep